The number of cervical cancer screening samples needing human review could be cut down by as much as 25 percent
The number of cervical cancer screening samples needing human review could be cut down by as much as 25 percent after the United Kingdom National Health Service Cancer Screening Programmes (NHSCSP) approved the use of an automated technology to screen the samples. Developed by Source BioScience, the BD FocalPoint can automatically screen cervical cancer samples and provides a “no further review necessary” signal should it find no problems with the samples.
The automated service is expected to cut down the number of samples that require human review by nearly 900,000 with over 3.6 million samples being reviewed every year in England and Wales.
Source-Medindia